NCT03670355View on ClinicalTrials.gov

Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 7, 2018

Primary Completion Date

September 25, 2019

Study Completion Date

September 25, 2019

Conditions
HIV Infections
Interventions
DRUG

Tenofovir (TFV) IVR

Contains 1.4 g TFV

DRUG

Placebo IVR

Contains placebo

Trial Locations (3)

15213

University of Pittsburgh CRS, Pittsburgh

35294

Alabama CRS, Birmingham

94143

Bridge HIV CRS, San Francisco

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03670355 - Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir | Biotech Hunter | Biotech Hunter